A Study of Diagnosis and Treatment of Depression Based on Biological Evidence of Dopamine Reward Pathway

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

300 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-06-01

Study Completion Date

2019-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will recruit depressed patients unresponsive to selective serotonin reuptake inhibitor antidepressant treatment, first-degree relatives (parents or siblings) of depressed patients, schizophrenia, Parkinson's disease with and without depression, and healthy controls. The subjects need to complete the brain positron emission tomography/magnetic resonance examination, stress assessment, genetic testing, clinical evaluation and neuropsychological tests. Using the data, this study aimed to identify the abnormalities of reward circuit of depression and its differences with other diseases, and its abnormalities in first-degree relatives of depression. The depressed patients who were ineffective in treatment with selective serotonin reuptake inhibitor antidepressants were then given combined medication with dopamine receptor-mediated drugs, including dopamine transporter inhibitor - bupropion, D2 receptor antagonist - risperidone, or D2 receptor partial agonist - aripiprazole, to examine the regulation of dopamine pathway and its relationship with the therapeutic effect. Through the above work, we will provide new evidence for integrating the biological evidence of dopamine reward pathway into the clinical practice of depression.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Diagnosis and Treatment Optimization Study of Depression Based on the Neurological Mechanism of Reward System

NCT03148522

Diagnosis and Treatment of Depression

UNKNOWN NA

Dopamine Neurotransmission in Major Depression

NCT01659814

Major Depressive Disorder Anhedonia

COMPLETED

Characterize the Regional Distribution of [11C] ABP688 in Brain by Positron Emission Tomography (PET)

NCT01528241

Depression

COMPLETED PHASE1

RCT of Brain Longitudinal Biomarker Study (OPT-Neuro RCT)

NCT05531591

Depression Dementia Mild Cognitive Impairment +5 more

COMPLETED PHASE4

Research on the Biological Mechanism of the Efficacy of Psychotherapy for Depression Based on the fNIRS

NCT05927129

Depressive Disorder

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diagnosis and Treatment of Depression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

bupropion

receive bupropion

Group Type EXPERIMENTAL

risperidone

Intervention Type DRUG

DA receptor-mediated drugs

risperidone

receive risperidone

Group Type EXPERIMENTAL

aripiprazole

Intervention Type DRUG

DA receptor-mediated drugs

aripiprazole

receive aripiprazole

Group Type EXPERIMENTAL

bupropion

Intervention Type DRUG

DA receptor-mediated drugs

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

risperidone

DA receptor-mediated drugs

Intervention Type DRUG

aripiprazole

DA receptor-mediated drugs

Intervention Type DRUG

bupropion

DA receptor-mediated drugs

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients unresponsive to SSRI antidepressant treatment, first-degree relatives (parents or siblings) of depressed patients, schizophrenia, Parkinson's disease with and without depression, and healthy controls

Exclusion Criteria

* Major physical illness; other DSM-IV axis I mental illness; personality disorder, mental retardation; drug and/or alcohol dependence; pregnant or lactating women; MRI examination contraindications.

Minimum Eligible Age

15 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes